#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: selpercatinib
#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC
1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ± ...
Selpercatinib showed promising clinical activity in tumour-agnostic patients with RET fusion-positive cancers other than thyroid and lung cancer
1. Objective response rate was 43.9%. Patients treated with selpercatinib also experienced improved overall response and time on treatment than ...
Selpercatinib continues to demonstrate effective response in RET fusion-positive NSCLC
1. Selpercatinib was found to have similar effective objective response rates compared to past studies in both treatment-naïve and chemotherapy ...
Selpercatinib may provide an effective response against RET-mutated thyroid cancer
1. Selpercatinib, a highly selective RET kinase inhibitor, was effective in antitumor activity against medullary thyroid cancer. 2. Selpercatinib caused ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
